In the present era, sophisticated electrophysiological interventional techniques have been developed for the treatment of paroxysmal supraventricular tachycardia, atrial flutter and ventricular tachycardia. However, the management of paroxysmal atrial fibrillation (PAF) still mainly depends on the use of antiarrhythmic agents. The occurrence of PAF is known to be unpredictable and sporadic (1) , which makes it difficult to evaluate the effects of antiarrhythmic drugs. Another problem with this arrhythmia is that somepatients are symptomatic and others are asymptomatic. Although Holter monitoring, which can detect asymptomatic arrhythmias, is used for assessing the treatment of ventricular arrhythmias, the sporadic and apparently transient occurrence of PAFmakes it unsuitable for study by Holter monitoring. In this issue of the Journal, Iga et al (2) 
